NON-breast HER2+ Malignancies Clinical Trial
Official title:
A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies
A first-in-human study using NJH395 in non-breast HER2-positive advanced malignancies
This study has two parts. There will be a single dose of NJH395 in the first part and multiple doses of NJH395 in the second part. After the first part is completed, the second part may open. ;